American drugmaker Merck to help produce J&J's Covid-19 vaccine: Biden

US President Joe Biden on Tuesday announced a collaboration between Johnson & Johnson, Merck, and the federal government to ramp up Covid-19 vaccine production

Johnson
Vials of J&J vaccine
ANI US
2 min read Last Updated : Mar 03 2021 | 7:00 AM IST

US President Joe Biden on Tuesday announced a collaboration between Johnson & Johnson, Merck, and the federal government to ramp up COVID-19 vaccine production.

This comes days after the Food and Drugs Administration (FDA) announced that it had approved the Janssen COVID-19 Vaccine for emergency use in the US in individuals 18 years of age and older.

Delivering his remarks at the White House, Biden announced the partnership: "Two of the largest health care and pharmaceutical companies in the world that are usually competitors are working together on the vaccine."

"This type of collaborations between the countries we have seen in World War II. We have also invoked the defence production act to equip Merck facilities to safely manufacture the J & J vaccine," he added

Biden said that because of a stepped-up production process, the United States will have enough novel coronavirus vaccines for every American adult by the end of May.

"This country will have enough vaccines supply for every adult in America by the end of May," Biden said on Tuesday.

The United States has reported more than 28.7 million confirmed Covid-19 cases and over 514,000 reported deaths. The demand for vaccines still far exceeds supply and these vaccines can't come soon enough.

The official emergency use authorization for Johnson & Johnson's (J & J) single-dose vaccine comes after an FDA advisory panel voted 22-0 to recommend authorization on Friday.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :MerckJohnson & JohnsonCoronavirus Vaccine

First Published: Mar 03 2021 | 6:52 AM IST

Next Story